SEC Form 4 · accession 0001209191-17-048791
Eloxx Pharmaceuticals, Inc. · ELOX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Opko Health, Inc.
10% Owner
Period of report
Aug 10, 2017
Accepted (ET)
Aug 14, 2017 · 5:15 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001035354
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 10, 2017 | C | 1,563,123 | $0.10 | A | 12,080,139 | D | |
| Common Stock | Aug 10, 2017 | C | 2,563,699 | $0.10 | A | 14,643,838 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Convertible Promissory NoteF3 | $0.10 | Aug 10, 2017 | C | — | D | Nov 10, 2016 | Nov 10, 2017 | Common Stock | 1,500,000 | 0 | D |
| Convertible Promissory NoteF3 | $0.10 | Aug 10, 2017 | C | — | D | Feb 24, 2017 | Aug 24, 2017 | Common Stock | 2,500,000 | 0 | D |
Explanation of responses
- F1Pursuant to the terms of the Convertible Note, the Reporting Person acquired (i) 1,500,000 shares of Common Stock upon conversion of $150,000 in principal amount of the Convertible Note, and (ii) 63,123 shares of Common Stock in accrued and previously unpaid interest thereon ($6,312.33).
- F2Pursuant to the terms of the Convertible Note, the Reporting Person acquired (i) 2,500,000 shares of Common Stock upon conversion of $250,000 in principal amount of the Convertible Note, and (ii) 63,699 shares of Common Stock in accrued and previously unpaid interest thereon (6,369.86).
- F3The derivative security was previously subject to a "blocker" pursuant to which the reporting person was unable to convert the derivative security to the extent such conversion would result in the reporting person owning more than 4.99%.